Loading...
Kellogg on Biotechnology: Thriving Through
Publisher description: Biotechnology is the new capital. The stakeholders in this revolution are many: the scientists who generate the knowledge in fields where the pace is maddeningly fast; the technologists who make ideas a reality; the managers who struggle to deal with an industry where the o...
| Main Author: | |
|---|---|
| Format: | Printed Book |
| Published: |
Kogan Page
2005
|
| Subjects: |
| LEADER | 02964nam a2200169Ia 4500 | ||
|---|---|---|---|
| 999 | |c 26876 |d 26876 | ||
| 020 | |a 9780749445287 | ||
| 082 | |a 660.6 KEL | ||
| 100 | |a Alicia Loffler [ Editor ] | ||
| 245 | |a Kellogg on Biotechnology: Thriving Through | ||
| 260 | |b Kogan Page |c 2005 | ||
| 300 | |a xiii, 264 pages : illustrations ; 23 cm | ||
| 505 | |a Promises and challenges of the U.S. stem cell industry / Whit Alexander and Shail Thaker -- Pharmacogenomics: overcoming the hurdles to adoption / Janette Chung, Peggy Mathias, and Rebecca Wildman -- Nanobiotechnology: applications and commercialization strategies / Badri Amurthur [and others] -- Sustaining platforms / Erich Hoefer [and others] -- Mergers and acquisitions as a strategic alternative in biotech / Andrew Ingley, Gregory Lief, and Jeanne Lukacek -- Biologics manufacturing: the make or buy decision / Anurag Bagaria -- Pharming factories / Andrew Ingley, James Pavlik, and Ty Smith -- The role of marketing / Dario Benavides [and others] -- To DTC or not to DTC: direct-to-consumer marketing in medical devices / Roy Katz [and others] -- The forgotten issue: reimbursement in biotechnology / Raj Changrani [and others]. | ||
| 520 | |a Publisher description: Biotechnology is the new capital. The stakeholders in this revolution are many: the scientists who generate the knowledge in fields where the pace is maddeningly fast; the technologists who make ideas a reality; the managers who struggle to deal with an industry where the old rules of thinking do not always apply; the venture capitalists who provide funds based on market moods rather than science; the health care, agricultural, chemical, and pharmaceutical industries whose once cozy enclaves have been revolutionized and are now barely recognizable; the law professionals and ethicists who have to grapple with issues unimaginable just a few years ago; the public policy makers who struggle with the complex issues and have to make decisions quickly, or risk being left behind; and, finally, the society and individuals who are in the midst of all that is taking place. This book addresses this diverse constituency and offers an integrated view of exciting new biotechnologies, both from a science and business perspective. The book walks the reader through the "what"--What are some of the newest biotechnologies that will revolutionize the way we think about health?; the "how"--how to transform those technologies into profitable products and companies; and the "who"--who will benefit from these technologies? Kellogg on Biotech is the outgrowth of a collaborative student-faculty effort called TechVentures at the Kellogg School of Management. Their research forms the raw material for Kellogg on Biotech. | ||
| 650 | |a Biotechnology. Biotechnology industries. Biomedical Technology. | ||
| 942 | |c BK | ||
| 952 | |0 0 |1 0 |4 0 |6 660_600000000000000_KEL |7 0 |9 29435 |a DCB |b DCB |d 2015-09-01 |l 0 |o 660.6 KEL |p DCB238 |r 2015-09-01 |w 2019-07-19 |y BK | ||